Medipower -M (MDPR) fair value: what the stock is really worth
As of Oct 9, 2026: fair value of Medipower -M ILS 4.04, price ILS 4.67, upside -13.5%, quality 58 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Oct 3, 2026.
How to read this chart
60‑month range 4.20 ILA – 8.52 ILA · fair‑value band 2.47 ILA – 6.49 ILA · the 4.67 ILA price screens above the 4.04 ILA fair value. Dashed = 300-day average. As of Oct 3, 2026.
Follow Medipower -M in your weekly email
Every Wednesday you see whether Medipower -M is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Medipower (Overseas) Public Co. Limited, together with its subsidiaries, operates as a commercial real estate company in the United States, Canada, and Bulgaria. It engages in the acquisition, rental, redevelopment, operation, and management of commercial income-generating real estate, primarily retail properties.
Show more
Medipower (Overseas) Public Co. Limited, together with its subsidiaries, operates as a commercial real estate company in the United States, Canada, and Bulgaria. It engages in the acquisition, rental, redevelopment, operation, and management of commercial income-generating real estate, primarily retail properties. The company was incorporated in 2001 and is based in Nicosia, Cyprus.
Stock analysis
Medipower -M (MDPR) currently trades at 4.67 ILA, while our model-based Fair Value estimate is 4.04 ILA, 13.5% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the DCF Models group reads highest at a median of 8.60 ILA per share, and 9 of the 14 models we run sit above the 4.67 ILA price.
Bear case: the Asset-Based group reads lowest at 1.66 ILA, and 5 of the 14 models stay below the price. Evidence for this calculation is medium.
Scenario range: 2.47 ILA (bear) to 6.49 ILA (bull), the price of 4.67 ILA sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 58/100 (solid quality), in the Real Estate sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
Medipower -M reported revenue of 44.8M ILA in FY2025 versus 30.8M ILA in FY2021, a compound +9.8%/yr. Reported net income was 13.5M ILA in FY2025, compounding +10.0%/yr from FY2021.
Key figures
Market cap 282M ILA · P/E ratio 38.6 · P/S ratio 11.6 · EPS (TTM) 0.1210 ILA · Net margin 30.1% · Return on equity 4.3% · Return on assets (EBIT) 5.3% · Operating margin 64.6%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 48 out of 100 (low confidence).
What moves the price
The share trades about 34% below its 52-week high and 1% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Real Estate peers we cover trades at −10% fair-value upside, at −13%, MDPR screens richer than that median.
Fair Value models
Bear 2.47 ILAFair Value 4.04 ILABull 6.49 ILA
Price 4.67 ILA · Upside -13.5%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2025 figures (about 9 months old). Earnings retained since then (0.0945 ILS per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
FCF DCF4.64 ILA6.84 ILA13.27 ILA74
Growth DCF4.29 ILA7.45 ILA12.38 ILA74
5Y EBITDA Exit4.86 ILA9.02 ILA17.17 ILA69
All 14 models by family
DCF Models
FCF DCF4.64 ILA6.84 ILA13.27 ILA74
5Y Revenue Exit3.67 ILA6.62 ILA12.77 ILA67
5Y EBITDA Exit4.86 ILA9.02 ILA17.17 ILA69
10Y Revenue Exit3.89 ILA8.60 ILA11.34 ILA64
10Y EBITDA Exit4.76 ILA10.78 ILA21.04 ILA62
Multiples
P/S Multiple2.91 ILA3.87 ILA4.84 ILA58
P/B Multiple2.91 ILA3.87 ILA4.84 ILA55
EV/EBIT6.68 ILA9.18 ILA11.69 ILA66
EV/EBITDA4.97 ILA6.91 ILA8.84 ILA67
EV/Revenue2.86 ILA4.46 ILA6.05 ILA53
Asset-Based
NCAV (Graham)1.24 ILA1.66 ILA2.48 ILA54
Growth DCF
Growth DCF4.29 ILA7.45 ILA12.38 ILA74
Rev-Margin DCF4.09 ILA7.52 ILA14.63 ILA66
Economic Profit
Residual Income1.91 ILA2.01 ILA2.24 ILA68
P/S and P/B multiple show the same value here: both are capped by the same earnings anchor (earnings per share times 17), because margin and return on equity do not support the sector multiple.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.81/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+14.4%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+6.1%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+13.3%
Start year 2020 (pandemic). Over 10 years: +14.1% a year
Revenue growth 19 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+8.5%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years) (mathematically smoothed) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Smoothed = median of all growth paths between the years of the window (trend line on the logarithm of earnings per share): a single extreme year cannot distort the rate. The reported figure stays in the tooltip.
+31.7%
Earnings growth per share plus dividend.
Earnings per share, growth per year+31.7%
Dividend (yield on the price)0.0%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.19.6% vs 11.4%, picking up
Profit margin 2006 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.53% → 60%
2025 sits 68% above its own trend. The rate follows the median trend of the last 5 years, not that single year.
Pace: the 5-year rate starts in 2020 (pandemic)
⚠ Revenue per share shrinking 2.4%/yr over ~10Y (margins intact) ⓘStructural-decline marker: revenue PER SHARE has fallen over the last decade (robust median trend, not a single year). Backtested across 2005 to 2017, such businesses trailed the market by about 2.5 percentage points per year. Display only: it does not change the fair value or the quality score.
Growth Forecast
Price in line with expectations
The price assumes about as much growth as the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+16.3%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (Israel: IMF forecast 2.1% a year to 2030, 1.7% from 2016 to 2025) that is about +13.9% a year for the price.
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Real Estate Services · 534 stocks
Beats the industry median on 6/13 measures
A mixed picture versus its industry peers.
Valuation
Quality Score58 · Above median
Fair Value upside−13.5% · Below median
Profitability
Return on equity (TTM)4.3% · Above median
Return on assets3.2% · Above median
Net margin (TTM)9.1% · Below median
Operating margin (TTM)64.6% · Top 25%
Growth and dividend
Revenue growth56.1% · Top 25%
Balance sheet
Debt / equity0.85× · Above median
Valuation Multiplesvs Real Estate Services median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Medipower -M Fair Value". https://www.fairvalue-calculator.com/stock/MDPR
Frequently asked questions
Is Medipower -M (MDPR) overvalued or undervalued?
As of Oct 3, 2026, our model estimates a fair value of 4.04 ILA versus a price of 4.67 ILA, about −13% upside (overvalued).
What is the fair value of MDPR?
Our model-based fair value for Medipower -M is 4.04 ILA (as of Oct 3, 2026), built from audited fundamentals. The current price: 4.67 ILA.
What is the quality score of MDPR?
Medipower -M has a Quality Score of 58/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Medipower -M (MDPR)?
Our model-based price target is the fair value of 4.04 ILA (as of Oct 3, 2026) from 14 valuation models. Cautious scenario 2.47 ILA, optimistic scenario 6.49 ILA. It is a calculation from audited fundamentals, not an analyst target.
What is the Medipower -M stock forecast for 2026?
Our models put fair value at 4.04 ILA, about −13% upside versus a price of 4.67 ILA (overvalued). Cautious scenario 2.47 ILA, optimistic scenario 6.49 ILA. The calculation is refreshed regularly with new filings.
What is the revenue of Medipower -M (MDPR)?
Medipower -M reported trailing-twelve-month revenue of about 48.6M ILS (latest available figure, as of Oct 3, 2026).
What growth is priced into Medipower -M (MDPR)?
For today's price to be fair in a discounted-cash-flow model, Medipower -M would have to grow free cash flow by +16.3 % per year for five years (discount rate 14.6 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +13.3 % per year. As of Oct 3, 2026.
What discount rate (WACC) does the fair value of MDPR use?
Our models discount Medipower -M at 14.6 %: a base by market capitalisation (micro), country premium for Israel. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Medipower -M that is +16.3 % per year a year over ten years, using the same discount rate (14.6 %) and the same formula as our fair value.
How much growth has Medipower -M (MDPR) delivered so far?
Over the past 5 years revenue at Medipower -M grew +13.3 % a year. The price currently implies +16.3 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Medipower -M (MDPR) growing?
The median revenue growth in the sector is +2.3 % a year. That is the yardstick for the growth priced into Medipower -M (+16.3 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Medipower -M (MDPR)?
The free-cash-flow yield on the price is 7.44 %: that much free cash flow Medipower -M produces per unit of market value. When it exceeds the discount rate of our models (14.6 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Medipower -M (MDPR)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Medipower -M it is 4.04 ILA per share (as of Oct 3, 2026), against a price of 4.67 ILA. It is the blended result of 14 valuation models (cash flow, earnings, asset, dividend).
Is Medipower -M stock overvalued or undervalued in 2026?
As of Oct 3, 2026, MDPR trades above its calculated fair value: price 4.67 ILA, fair value 4.04 ILA, a gap of about −13% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of MDPR?
No. The price is what the market pays today (4.67 ILA); the fair value is what the company's own numbers justify (4.04 ILA). For Medipower -M the two are 0.6290 ILA per share apart. That gap is exactly why we show both numbers side by side.
How much is Medipower -M worth?
The market values Medipower -M at about 282M ILA (market capitalisation, as of Oct 3, 2026). Per share that is 4.67 ILA; our models calculate a fair value of 4.04 ILA per share.
What do the bullish and bearish scenarios say about MDPR?
Our models span a range for Medipower -M: cautious scenario 2.47 ILA, base 4.04 ILA, optimistic 6.49 ILA per share (as of Oct 3, 2026, price 4.67 ILA). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of MDPR?
Medipower -M trades at a price-to-earnings ratio of 38.6 (as of Oct 3, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of 4.04 ILA is built from several models across several years. Other multiples: P/B 1.9, P/S 5.8, EV/EBITDA 9.0.
How solid is the balance sheet of Medipower -M (MDPR)?
Balance-sheet figures for Medipower -M (as of Oct 3, 2026): return on equity 4.3%, debt of 0.85 per unit of equity. They feed the Quality Score of 58/100, which measures business quality independently of the share price.
How far is MDPR from its 52-week high?
Medipower -M trades at 4.67 ILA, about 34% below its 52-week high of 7.10 ILA and 1% above the low of 4.61 ILA (as of Oct 9, 2026). Distance from the high says nothing about value: that is what the fair value of 4.04 ILA is for.
Which stocks are comparable to Medipower -M?
From the same area (Real Estate) we also value Vingroup Joint Stock Company, CBRE Group, KE Holdings, Swire Properties Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Medipower -M stock attractive at the current price?
The data as of Oct 3, 2026: price 4.67 ILA, calculated fair value 4.04 ILA (−13%), Quality Score 58/100, from 14 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of MDPR calculated?
We run Medipower -M through 14 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of 4.04 ILA, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.9 % above its aggregate fair value. Medipower -M itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Medipower -M (MDPR)?
The closing price on Oct 9, 2026 was 4.67 ILA. Our model-based fair value is 4.04 ILA, about −13% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Medipower -M right now?
The model range is unusually wide (2.47 ILA to 6.49 ILA). The outcome hinges heavily on assumptions, so read the point estimate with caution. Solid but not exceptional quality (58/100) and above fair value, neither a clear bargain nor a standout compounder. As a real-estate business, asset- and dividend-based methods carry more weight here than a standard DCF.
Key figures of Medipower -M
How large is the market capitalisation of Medipower -M (MDPR)?
The market capitalisation of Medipower -M is 282M ILA. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Medipower -M (MDPR)?
The price-to-sales ratio of Medipower -M is 11.6 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Medipower -M (MDPR)?
Earnings per share at Medipower -M are 0.1210 ILA (price ÷ EPS = P/E 38.6). Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Medipower -M (MDPR)?
The net margin of Medipower -M is 30.1% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Medipower -M (MDPR)?
The return on equity (ROE) of Medipower -M is 4.3% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Medipower -M (MDPR)?
On an EBIT basis the return on assets of Medipower -M is 5.3% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Medipower -M (MDPR)?
The operating margin of Medipower -M is 64.6% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Medipower -M (MDPR)?
Revenue at Medipower -M is growing +56.1% versus a year earlier (3y avg +6.1%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Medipower -M (MDPR)?
Earnings per share at Medipower -M are growing +149% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does Medipower -M (MDPR) carry?
The net debt of Medipower -M is 277M ILA (fiscal year 2025, ≈ 15.6 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Medipower -M in the live analysis
One click puts Medipower -M on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener.
